Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced that its President and CEO, Russell Trenary, participated in a Virtual Investor CEO Connect segment. The segment, now available for viewing, provided an overview of the company's recent achievements and upcoming milestones. Outlook Therapeutics recently gained regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). The company is working towards becoming the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced its participation in the Virtual Investor Closing Bell Series. Russell Trenary, President and CEO, will present on Thursday, September 19, 2024, at 4:00 PM ET. The event will include a corporate overview, business outlook, and a live Q&A session.
Notably, Outlook Therapeutics recently achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). This milestone highlights the company's progress in the ophthalmology field.
Investors can access the live video webcast on the company's website, with a replay available for 90 days post-event.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series. The company, which gained regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD), was featured among 8 companies at the event. The conference focused on AMD and diabetes-related ocular diseases.
As part of the virtual event, Outlook Therapeutics' executives Russell Trenary (President and CEO) and Lawrence Kenyon (CFO) participated in a fireside chat hosted by Chardan's Senior Research Analyst, Daniil Gataulin, PhD. A video webcast of this discussion is now available for viewing online.
Outlook Therapeutics (Nasdaq: OTLK) has announced the completion of enrollment for its NORSE EIGHT clinical trial, evaluating ONS-5010 in wet AMD patients. This trial, subject to a Special Protocol Assessment (SPA) agreement with the FDA, is the final anticipated clinical study before the expected resubmission of the company's Biologics License Application (BLA) for ONS-5010.
Key points:
- NORSE EIGHT is a randomized, controlled study comparing ONS-5010 to ranibizumab
- Topline results are expected in Q4 2024
- BLA resubmission is planned for Q1 2025
- The trial aims to address the clinical deficiency identified in the previous Complete Response Letter
If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/LYTENAVA™ (bevacizumab-vikg) directly in the U.S. and is exploring partnering options for Europe and other regions.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Russell Trenary, President and CEO, will present at the conference and be available for one-on-one meetings with qualified investors.
The company recently achieved regulatory approval in the European Union and the United Kingdom for the first authorized ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET for registered attendees and on the company's website for 90 days following the event.
Outlook Therapeutics (Nasdaq: OTLK) reported financial results for Q3 FY2024 and provided a corporate update. Key highlights include:
1. Received EU and UK Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for wet AMD treatment.
2. NORSE EIGHT clinical trial enrollment on track for Q3 CY2024 completion, with topline results expected in Q4 CY2024.
3. ONS-5010 BLA resubmission targeted for Q1 CY2025.
4. Reported net income of $44.4 million, or $1.91 per basic share, compared to a net loss of $20.7 million in the same period last year.
5. Cash and cash equivalents of $32.0 million as of June 30, 2024.
6. Commercial launch of LYTENAVA™ in EU and UK anticipated in H1 CY2025.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Russell Trenary, President and CEO, will engage in a fireside chat during the event.
The video webcast of the fireside chat will be available on-demand starting at 7:00 AM ET on August 15 for registered attendees. It will also be accessible on the company's website in the Investors section's Events page. The webcast replay will remain archived for 90 days after the event.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company that has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab to treat wet AMD, has announced its upcoming financial results release. The company will report its third quarter fiscal year 2024 results on Wednesday, August 14, 2024. Following the release, management will host a conference call and live audio webcast at 8:30 AM ET to discuss operational and financial outcomes.
The call will be led by Russell Trenary, President and CEO, and Lawrence Kenyon, CFO. Investors can join the call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international). A live webcast will also be available on the company's website and archived for 90 days.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases, announced its participation in the BTIG Virtual Biotechnology Conference 2024. Russell Trenary, President and CEO, will engage in a fireside chat on Monday, August 5th at 8:00 AM ET.
The company's management team will also be available for one-on-one virtual meetings with qualified investors attending the conference. Interested parties are advised to contact their BTIG representative to schedule meetings with Outlook Therapeutics during the event.
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This follows a similar approval by the European Commission. The commercial launch in the UK and EU is anticipated for Q1 2025. Outlook Therapeutics has partnered with Cencora to support these launches, ensuring market access and efficient distribution. The MHRA's approval marks a significant milestone, offering the first authorized ophthalmic bevacizumab for wet AMD in these regions.